Inflammatory bowel disease, to personalized nutrition
DOI:
https://doi.org/10.14306/renhyd.18.1.36Keywords:
Inflammatory bowel diseases, Diet, Nutrition therapy, Nutrigenomics, Epigenomics, EpidemiologyAbstract
The incidence of inflammatory bowel disease (IBD) is increasing in countries that acquire a Western lifestyle. Its pathogenesis is not well defined but is associated with multifactorial causes. In genetically predisposed people, different environmental factors trigger alterations in the immune response; as a result, tolerance is lost towards commensal gut microbiota, with tissues damage and chronic inflammation. Among the environmental risk factors identified is diet. Diets high in sucrose, refined carbohydrates, omega-6 polyunsaturated fatty acids, and low in fruit, vegetables, and fiber are associated with an increased risk of IBD, particularly Crohn disease (CD). Nutritional recommendations in IBD cannot be generalized because patients respond differently. The emergence of disciplines such as nutrigenetics, nutrigenomics and epigenetics allow a greater understanding of the pathogenesis of the disease, and at the same time, it opens up the possibility to an individualized approach from the nutritional standpoint. An example of this is found in carriers of the polymorphism 857C/T in the gene TNF (Tumor Necrosis Factor), in which a diet high in saturated and monounsaturated fatty acids is harmful and is associated with a more active disease phenotype. This paper reviews the latest scientific articles in these disciplines in relation to IBD and nutritional potential therapeutic applications, like antioxidants application or the ratio of polyunsaturated fatty acids v-6/v-3. It was used the database of the National Center for Biotechnology Information (NCBI) to search for articles, including selecting the most interest from 2007 to 2012.
References
Neuman MG, Nanau RM. Inflammatory bowel disease: Role of diet, microbiota, life style. Transl Res. 2012; 160(1): 29-44.
Haller D. Nutrigenomics and IBD: the intestinal microbiota at the cross-road between inflammation and metabolism. J Clin Gastroenterol. 2010; 44 Suppl 1: S6-9.
Ferguson LR. Nutrigenomics and inflammatory bowel diseases. Expert Rev Clin Immunol. 2010; 6(4): 573-83.
Sicilia B, Vicente R, Gomollón F. [Epidemiology of inflammatory bowel disease: controversies in classical epidemiology]. Acta Gastroenterol Latinoam. 2009; 39(2): 135-45.
Tighe MP, Cummings JR, Afzal NA. Nutrition and inflammatory bowel disease: primary or adjuvant therapy. Curr Opin Clin Nutr Metab Care. 2011; 14(5): 491-6.
Hanauer SB, Hommes DW. Inflammatory bowel disease. Expert Rev Clin Immunol. 2010; 6(4): 499-500.
Innis SM, Jacobson K. Dietary lipids in early development and intestinal inflammatory disease. Nutr Rev. 2007; 65(12 Pt 2): S188-93.
Gruber L, Lichti P, Rath E, Haller D. Nutrigenomics and nutrigenetics in inflammatory bowel diseases. J Clin Gastroenterol. 2012; 46(9): 735-47.
Albenberg LG, Lewis JD, Wu GD. Food and the gut microbiota in inflammatory bowel diseases: a critical connection. Curr Opin Gastroenterol. 2012; 28(4): 314-20.
Gentschew L, Ferguson LR. Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases. Mol Nutr Food Res. 2012; 56(4): 524-35.
Hammer HF. Gut microbiota and inflammatory bowel disease. Dig Dis. 2011; 29(6): 550-3.
Veerappan GR, Betteridge J, Young PE. Probiotics for the treatment of inflammatory bowel disease. Curr Gastroenterol Rep. 2012; 14(4): 324-33.
Tlaskalová-Hogenová H, Steˇpánková R, Kozáková H, Hudcovic T, Vannucci L, Tucˇková L, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011; 8(2): 110-20.
Olivares M, Laparra JM, Sanz Y. Host genotype, intestinal microbiota and inflammatory disorders. Br J Nutr. 2013; 109 Suppl 2: S76-80.
Hakansson A, Molin G. Gut microbiota and inflammation. Nutrients. 2011; 3(6): 637-82.
Hedin CR, Stagg AJ, Whelan K, Lindsay JO. Family studies in Crohn’s disease: new horizons in understanding disease pathogenesis, risk and prevention. Gut. 2012; 61(2): 311-8.
Ferguson LR, Philpott M, Dryland P. Nutrigenomics in the whole-genome scanning era: Crohn’s disease as example. Cell Mol Life Sci. 2007; 64(23): 3105-18.
Lee G, Buchman AL. DNA-driven nutritional therapy of inflammatory bowel disease. Nutrition. 2009; 25(9): 885-91.
Ferguson LR, Shelling AN, Browning BL, Huebner C, Petermann I. Genes, diet and inflammatory bowel disease. Mutat Res. 2007; 622(1-2): 70-83.
Morgan AR, Lam WJ, Han DY, Fraser AG, Ferguson LR. Genetic variation within TLR10 is associated with Crohn’s disease in a New Zealand population. Hum Immunol. 2012; 73(4): 416-20.
Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR, et al. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn’s disease in a New Zealand population. Mutat Res. 2010; 690(1-2): 108-15.
Ferguson LR, Huebner C, Petermann I, Gearry RB, Barclay ML, Demmers P, et al. Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. World J Gastroenterol. 2008; 14(29): 4652-61.
Barnett M, Bermingham E, McNabb W, Bassett S, Armstrong K, Rounce J, et al. Investigating micronutrients and epigenetic mechanisms in relation to inflammatory bowel disease. Mutat Res. 2010; 690(1-2): 71-80.
Huebner C, Browning BL, Petermann I, Han DY, Philpott M, Barclay M, et al. Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflamm Bowel Dis. 2009; 15(12): 1784-93.
Baines KJ, Wood LG, Gibson PG. The nutrigenomics of asthma: molecular mechanisms of airway neutrophilia following dietary antioxidant withdrawal. OMICS. 2009; 13(5): 355-65.
Simmons JD, Mullighan C, Welsh KI, Jewell DP. Vitamin D receptor gene polymorphism: association with Crohn’s disease susceptibility. Gut. 2000; (47): 211-4.
Guerreiro CS, Ferreira P, Tavares L, Santos PM, Neves M, Brito M, et al. Fatty acids, IL6, and TNFalpha polymorphisms: an example of nutrigenetics in Crohn’s disease. Am J Gastroenterol. 2009; 104(9): 2241-9.
Aoyagi Y, Nagata S, Kudo T, Fuji T, Wada M, Chiba Y, et al. Peroxisome proliferator-activated receptor g 2 mutation may cause a subset of ulcerative colitis. Pediatr Int. 2010; 52: 729–34.
Calder PC. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res. 2008; 52(8): 885-97.
Borthakur A, Bhattacharyya S, Dudeja PK, Tobacman JK. Carrageenan induces interleukin-8 production through distinct Bcl10 pathway in normal human colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2007; 292(3): G829-38.
Danesi F, Philpott M, Huebner C, Bordoni A, Ferguson LR. Food-derived bioactives as potential regulators of the IL-12/IL-23 pathway implicated in inflammatory bowel diseases. Mutat Res. 2010; 690(1-2): 139-44.
Kellermayer R. Epigenetics and the developmental origins of inflammatory bowel diseases. Can J Gastroenterol. 2012; 26(12): 909-15.
Ferguson LR. Potential value of nutrigenomics in Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2012; 9(5): 260-70.
Gentschew L, Bishop KS, Han DY, Morgan AR, Fraser AG, Lam WJ, et al. Selenium, selenoprotein genes and Crohn’s disease in a case-control population from Auckland, New Zealand. Nutrients. 2012; 4(9): 1247-59.
This journal 